Generative AI is beginning to reshape not only how medicines are discovered, but also how investors classify the companies building that technology. Insilico Medicine will join the HKEX Tech 100 Index in September, placing the AI-driven drug discovery company alongside Hong Kong-listed businesses representing artificial intelligence, biotechnology, robotics and other technology themes.
The boundary between artificial intelligence and biotechnology is becoming harder to draw.
Insilico Medicine’s upcoming inclusion in the HKEX Tech 100 Index offers another indication of that shift. The clinical-stage drug discovery company, listed in Hong Kong under stock code 3696, will be added following changes to the index methodology that broaden its coverage of emerging technology trends, including opportunities across the AI value chain.
The changes will be implemented after the market close on September 11, 2026, and take effect September 14.
For Insilico, the development is more than an index change. It places an AI-native drug discovery company within a technology benchmark designed to capture some of the largest Hong Kong-listed companies with significant exposure to technology and innovation themes.
The HKEX Tech 100 was launched in December 2025 and tracks 100 eligible Hong Kong-listed companies across six themes: artificial intelligence, biotech and pharmaceuticals, electric vehicles and smart driving, information technology, internet and robotics. Constituents must also be eligible for Southbound Stock Connect.
HKEX announced the methodology changes in August, saying the revisions are intended to make the index more representative of the region’s changing technology landscape and broaden its exposure to emerging areas across the AI value chain.
That creates an interesting context for Insilico.
The company’s core proposition is not simply applying an existing AI model to pharmaceutical research. Its Pharma.AI platform combines AI-based target identification, generative chemistry and clinical development analysis. Its leading program, Rentosertib, illustrates the end-to-end approach.
Insilico used PandaOmics to identify and prioritize TNIK as a potential target for idiopathic pulmonary fibrosis, then used its generative chemistry platform, Chemistry42, to design and optimize a small-molecule candidate. The company also uses InClinico for clinical-trial forecasting and development analysis.
Rentosertib has now reached Phase III development, making it one of the most closely watched examples of generative AI progressing from biological discovery into late-stage clinical development.
Insilico initiated the global Phase III program in July 2026. The company describes Rentosertib as the first program in which both the target and molecular structure were identified or generated using generative AI to reach pivotal-stage development.
That milestone matters because AI drug discovery has spent much of the past decade being evaluated on potential rather than clinical outcomes.
Finding a molecule computationally is only one part of pharmaceutical development. Candidates still have to demonstrate safety, pharmacological activity, appropriate dosing and efficacy through increasingly demanding clinical trials.
Rentosertib’s progress does not establish that generative AI can consistently produce successful medicines. It does, however, provide a more concrete test of whether AI-native discovery platforms can move programs through the pharmaceutical development pipeline.
Insilico is also attempting to demonstrate that the model can scale.
The company reported $106.3 million in revenue during the first half of 2026, up 287.2% year over year, according to its interim results. Adjusted net profit reached $51.23 million, while revenue from drug discovery and pipeline development exceeded $103 million. The company attributed much of the growth to upfront and milestone payments from business-development agreements.
That commercial model is important for understanding AI-native biotech.
Unlike conventional software companies, drug discovery companies cannot measure success simply through model adoption or subscription revenue. Their platforms ultimately have to generate valuable intellectual property, clinical assets, licensing agreements and, potentially, approved medicines.
Insilico has pursued partnerships with pharmaceutical companies including Eli Lilly, Servier and Takeda, among others. Those relationships provide a route for AI-generated discoveries to enter larger pharmaceutical development and commercialization organizations.
The investment story is consequently tied to two markets at once: AI and biotechnology.
That intersection is becoming increasingly significant as pharmaceutical companies look for computational approaches that can reduce the time and cost associated with identifying drug candidates. Generative models can search chemical spaces, propose molecular structures and help researchers evaluate potential targets, although experimental validation remains essential.
Insilico’s strategy also reflects a broader movement toward AI-native biotech, in which AI is integrated into the core research workflow rather than used as a supplementary productivity tool.
Companies such as Recursion, Schrödinger and Generate are pursuing different approaches to computational drug discovery, while established pharmaceutical companies are building internal AI capabilities and partnering with specialized technology providers.
The competitive question is therefore shifting.
It is no longer simply whether AI can assist scientists. The more consequential question is whether AI-driven platforms can repeatedly produce clinically and commercially valuable drug candidates.
The HKEX Tech 100 inclusion also comes with a capital-markets dimension. Because the index requires constituents to be eligible for Southbound Stock Connect, inclusion potentially expands the company’s visibility among mainland Chinese investors accessing Hong Kong-listed equities through the Connect mechanism.
An ETF tracking the HKEX Tech 100 began trading in June 2026, providing investors with a passive investment vehicle linked to the benchmark.
That does not guarantee passive inflows into every newly added constituent, nor does index inclusion validate a company’s clinical pipeline. But it can increase visibility and make the company easier to access through technology-focused investment products.
For Insilico, the timing is notable.
The company is entering the index as its most prominent AI-generated drug program advances into Phase III and as its licensing and collaboration business becomes a larger source of revenue.
The broader message is that AI is increasingly being recognized as an infrastructure layer for scientific discovery—not merely a software category.
If Rentosertib and subsequent programs continue to advance, Insilico will provide a useful real-world case study of what happens when generative AI moves from predicting and designing molecules to influencing actual clinical development.
The HKEX Tech 100 inclusion does not settle that question. But it signals that the market is increasingly willing to treat AI-driven drug discovery as part of the technology economy itself.
Market Landscape
AI drug discovery sits at the intersection of several rapidly developing markets: generative AI, computational biology, pharmaceutical R&D and biotechnology.
The field includes AI-native companies such as Insilico Medicine and Recursion, computational chemistry companies such as Schrödinger, and major pharmaceutical organizations developing proprietary AI capabilities or forming partnerships with AI companies.
The technology stack is also becoming more sophisticated. Modern platforms can combine biological datasets, multi-omics information, literature and patent intelligence, molecular generation, virtual screening and clinical-development modeling.
The difficult part remains translation.
AI can help researchers narrow enormous search spaces, but candidates still require laboratory validation and clinical trials. The industry is therefore moving from demonstrations of AI capability toward evidence of pipeline productivity, clinical milestones and commercial returns.
Insilico’s Rentosertib is particularly relevant because the program has progressed into Phase III after its target identification and molecular design stages incorporated generative AI.
At the capital-markets level, HKEX is also expanding its technology-index ecosystem. Its Tech 100 now explicitly spans AI, biotech and pharmaceuticals, robotics and other technology themes, while the exchange has introduced additional technology-focused benchmarks in 2026.
Top Insights
- Insilico Medicine will join the HKEX Tech 100 after HKEX expanded the index methodology to capture emerging technology trends across the AI value chain.
- The company’s Rentosertib program has entered Phase III, providing a high-profile test of whether generative AI can produce clinically meaningful drug candidates.
- Insilico’s Pharma.AI platform combines AI-powered target discovery, generative chemistry and clinical development analysis across the drug-development workflow.
- First-half 2026 revenue reached $106.3 million, reflecting growing licensing, milestone and collaboration activity around the company’s AI-driven pipeline.
- The index inclusion highlights a broader convergence between AI and biotechnology as computational discovery becomes increasingly central to pharmaceutical R&D.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
